Shots:
- Redx to receive $17M in early payment by the time of successful commencement of a P-I study, $360M as development, a regulatory and commercial milestone along with royalties on sales of the RXC006
- AstraZeneca to get an exclusive global license to further develop & commercialize RXC006 targeting fibrotic diseases including IPF
- Redx continues to progress its lead oncology asset, RXC004 (porcupine inhibitor) targeting Wnt-driven tumors, currently being evaluated in P-I/II clinical trial, and RXC007, the oral Rock 2 inhibitor targeting fibrosis where first in human studies are expected in 2021
Click here to read full press release/ article | Ref: AstraZeneca | Image: SoPosted
